The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients

摘要: Triple-negative breast cancers comprise about 20 % of cancers. They have poor prognosis and no standard therapy. The aim this study was to evaluate pathologic complete response (pCR), progression-free survival (PFS), overall (OS) in patients with TNBC treated neoadjuvant platinum-based chemotherapy. This is a retrospective one hundred forty-four women platinum-containing chemotherapy for locally advanced cancer at the University Miami between January 1, 1999, 2011. medical record reviewed obtain data on clinical characteristics, including ethnicity, race, age, stage, treatment regimen, vital status. approved by IRB. All had least following features presentation: T3, T4, N2, N3. mean tumor size palpation 9.4 cm. T-stage presentation 1.4 T1, 8.3 T2, 52.8 37.5 T4 (19.4 T4d). nodal status physical exam 23 N0, N1, 34 5.5 pCR axilla seen 31 %. PFS OS were 55 59 %, respectively, 7 years. Cisplatin offered advantage over carboplatin both (P = 0.007) 0.018). Node positivity most important predictor survival. Cisplatin/docetaxel therapy well tolerated an effective TNB.